Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus TOLTERODINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus TOLTERODINE TARTRATE.
LUSEDRA vs TOLTERODINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5) with relative selectivity for the bladder over salivary glands. Reduces detrusor muscle contractility and bladder pressure.
5 mg orally once daily.
2 mg orally twice daily. May be reduced to 1 mg orally twice daily based on tolerability.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life is 2-3 hours in extensive metabolizers (CYP2D6) and approximately 9 hours in poor metabolizers. In clinical context, dosing interval is adjusted in poor metabolizers (e.g., 2 mg twice daily reduced to 2 mg once daily).
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Renal (77%) and fecal (17%): approximately 14% as unchanged tolterodine, 51% as the active 5-hydroxymethyl metabolite, and 12% as other metabolites. Biliary excretion contributes minimally.
Category C
Category A/B
Anticholinergic
Anticholinergic